Trump Administration Expands Manufacturing Capacity with Cytiva for Components of COVID-19 Vaccines

COVID-19

To meet the Trump Administration’s Operation Warp Speed goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) this week announced an agreement with Cytiva, headquartered in Massachusetts, to expand the company’s manufacturing capacity for products that are essential in producing COVID-19 vaccines.

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, collaborated with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command, to provide approximately $31 million to Cytiva for vaccine-related consumable products, such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and XDR bioreactors.

“As part of Operation Warp Speed, we are expanding U.S.-based manufacturing of the products that are essential in the development and manufacturing of COVID-19 vaccines,” said HHS Secretary Alex Azar. “By expanding capacity now, not only do we help deliver these products as quickly as possible, but we also return manufacturing to America, boosting the economy and preparing us for future crises.”

READ:  Octorara Area School District Returns to Remote Learning Beginning Monday, November 30

Under the agreement, the company will expand manufacturing capacity in the company’s Massachusetts facilities and create duplicate capabilities in Cytiva’s Utah facilities to be complete in less than 12 months. Currently, the company only manufactures consumables in Massachusetts.

Cytiva is a major manufacturer of pharmaceutical consumables and hardware products and the primary supplier to many of the companies currently working with the U.S. government to develop COVID-19 vaccines. This capacity expansion will help Cytiva respond to the demand for COVID-19 vaccine consumables and hardware products without impacting on current manufacturing output.

The agreement with Cytiva is the latest to increase manufacturing capacity in the United States to aid in developing, manufacturing, and administering COVID-19 vaccines and therapeutics.

To date, the federal government has obligated a total of more than $1.1 billion to purchase needles, syringes, vials and supply kits, and to expand the capacity to manufacture these ancillary supplies and the fill-finish manufacturing capacity in the United States for COVID-19 vaccines and therapeutics. HHS and DOD are working with Becton Dickinson, Corning Pharmaceutical Technologies, Goldbelt Security, Marathon Medical, Retractable Technologies Inc., SiO2, ApiJect, Smiths Medical, and Thermo Fisher Scientific. BARDA also is working with its Centers for Innovation in Advanced Development and Manufacturing in Maryland and Texas to expand vaccine manufacturing capacity for federal vaccine development partners.

READ:  November 23 Coronavirus Update: 506 New Positives Brings Total to 11,080 COVID-19 Cases in Chester County

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee